Dr Reddy’s lenacapavir gets tentative USFDA nod
In short
Dr Reddy’s injectable lenacapavir for HIV prevention got tentative approval from the USFDA. The first supplies are expected by the end of 2026, and a wider rollout is expected in 2027.
This matters because it could broaden access to an HIV-prevention drug for people in eligible countries. The reporting does not say when final approval will happen or where the first launch will be.
What the reporting says
Dr Reddy’s injectable lenacapavir for HIV prevention got tentative approval from the USFDA, according to the available reporting. The source says first supplies are expected to reach people by the end of 2026, with a broader rollout across eligible countries expected in 2027. The reporting does not say when final approval will come or where the launch will begin.
Why it matters
Dr Reddy’s injectable lenacapavir for HIV prevention received tentative USFDA nod, with first supplies expected by end-2026 and broader rollout in 2027. That points to a potential future product supply event for the company and for people eligible for HIV prevention access. The reporting does not state the final approval timeline, launch geography, or commercial terms, so the immediate operational impact is still uncertain.